# Safety/Efficacy Study of LDE225 (Sonidegib) Plus Bortezomib in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma

> **NCT02254551** · PHASE2 · TERMINATED · sponsor: **SCRI Development Innovations, LLC** · enrollment: 7 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** LDE225
- **DRUG:** Bortezomib

## Key facts

- **NCT ID:** NCT02254551
- **Lead sponsor:** SCRI Development Innovations, LLC
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-01
- **Primary completion:** 2015-10
- **Final completion:** 2015-10
- **Target enrollment:** 7 (ACTUAL)
- **Why stopped:** Safety lead-in data did not support continuation of study.
- **Last updated:** 2017-02-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02254551

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02254551, "Safety/Efficacy Study of LDE225 (Sonidegib) Plus Bortezomib in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02254551. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*